Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RYR2 | Q92736 | 6/20 | 1.00 |
| ▸ | CDK1 | P06493 | 3/20 | 0.53 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.53 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17892772 | 0.91 | RYR2 (0.84) | RYR2CDK1MAPKAPK2PRKD1KCNH2 | |
| SCHEMBL14691928 | 0.88 | RYR2 (0.78) | RYR2CDK1MAPKAPK2PRKD1KCNH2 | |
| SCHEMBL2600209 | 0.80 | RYR2 (0.66) | RYR2KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL30804421 | 0.78 | RYR2 (0.63) | RYR2CDK1MAPKAPK2PRKD1KCNH2 | |
| SCHEMBL11283 | 0.76 | KDM4E (0.77) | RYR2KCNH2KDM4EHTTMAOA | |
| SCHEMBL29596397 | 0.76 | KDM4E (0.77) | RYR2KCNH2KDM4EHTTMAOA | |
| SCHEMBL1238947 | 0.76 | RYR2 (0.61) | RYR2CDK1MAPKAPK2PRKD1HTT | |
| SCHEMBL9636752 | 0.76 | RYR2 (0.61) | RYR2CDK1MAPKAPK2PRKD1KCNH2 | |
| SCHEMBL7222447 | 0.74 | KDM4E (0.63) | RYR2KCNH2KDM4EHTTMAOA | |
| SCHEMBL17892752 | 0.74 | RYR2 (0.58) | RYR2CDK1MAPKAPK2PRKD1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230386615-A1 | BINDING SITE IN TYPE 1 RYANODINE RECEPTOR | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2023-11-30 | — | — | US | disclosed |
| US-20230368862-A1 | BINDING SITE IN TYPE 2 RYANODINE RECEPTOR | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2023-11-16 | — | — | US | disclosed |
| US-20230368862-A1 | BINDING SITE IN TYPE 2 RYANODINE RECEPTOR | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2023-11-16 | — | — | US | disclosed |
| EP-3240547-A1 | NOVEL CALCIUM MODULATORS | Myotherix Inc. (US) | 2017-11-08 | — | — | EP | disclosed |
| US-20160214973-A1 | STORE OVERLOAD-INDUCED CALCIUM RELEASE INHIBITORS AND METHODS FOR PRODUCING AND USING THE SAME | UTI LIMITED PARTNERSHIP (CA) | 2016-07-28 | — | — | US | disclosed |
| US-20160207893-A1 | NOVEL CALCIUM MODULATORS | MYOTHERIX, INC. | 2016-07-21 | — | — | US | disclosed |
| US-20160207893-A1 | NOVEL CALCIUM MODULATORS | MYOTHERIX, INC. | 2016-07-21 | — | — | US | disclosed |
| US-20160207893-A1 | NOVEL CALCIUM MODULATORS | MYOTHERIX, INC. | 2016-07-21 | — | — | US | disclosed |
| WO-2016109596-A1 | NOVEL CALCIUM MODULATORS | MYOTHERIX, INC. (US) | 2016-07-07 | — | — | WO | disclosed |
| US-8933129-B2 | Compounds and methods for modulating activity of calcium release channels | STATE OF OREGON BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF PORTLAND STATE UNIVERSITY (US) | 2015-01-13 | — | — | US | disclosed |
| US-20070173482-A1 | Agents for preventing and treating disorders involving modulation of the RyR receptors | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2007-07-26 | — | — | US | disclosed |
| US-20070173482-A1 | Agents for preventing and treating disorders involving modulation of the RyR receptors | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2007-07-26 | — | — | US | disclosed |
| WO-2007024717-A2 | AGENTS FOR PREVENTING AND TREATING DISORDERS INVOLVING MODULATION OF THE RYR RECEPTORS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20070049572-A1 | Novel agents for preventing and treating disorders involving modulation of the RyR receptors | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2007-03-01 | — | — | US | disclosed |
| US-20070049572-A1 | Novel agents for preventing and treating disorders involving modulation of the RyR receptors | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2007-03-01 | — | — | US | disclosed |
| US-20040229781-A1 | Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2004-11-18 | — | — | US | disclosed |
| US-20040229781-A1 | Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2004-11-18 | — | — | US | disclosed |
| EP-0565721-B1 | 1,4-BENZOTHIAZEPINE DERIVATIVE | KANEKO NOBORU (JP) | 1995-07-26 | — | — | EP | disclosed |
| US-5416066-A | FOR THE PREVENTION OF MYOCARDIAL INFARCTION OR INHIBITING MYOCARDIAL NECROSIS | KIRIN BREWERY CO., LTD. (JP) | 1995-05-16 | — | — | US | disclosed |
| EP-0565721-A1 | 1,4-BENZOTHIAZEPINE DERIVATIVE | KANEKO, Noboru (JP) | 1993-10-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173482-A1 | Agents for preventing and treating disorders involving modulation of the RyR receptors | RYR1, RYR2, ATP2A1 | RYR2 2/4885CDK1 1840/4885MAPKAPK2 3456/4885 |
| US-20070049572-A1 | Novel agents for preventing and treating disorders involving modulation of the RyR receptors | RYR2, RYR1, ATP2A1 | RYR2 1/4885CDK1 408/4885MAPKAPK2 2045/4885 |
| US-20160207893-A1 | NOVEL CALCIUM MODULATORS | CACNA1E, CASR, CACNA1D | RYR2 17/4885CDK1 1730/4885MAPKAPK2 3257/4885 |
| US-20040229781-A1 | Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias | RYR2, RYR1, FKBP4 | RYR2 1/4885CDK1 2345/4885MAPKAPK2 2498/4885 |
| US-20160214973-A1 | STORE OVERLOAD-INDUCED CALCIUM RELEASE INHIBITORS AND METHODS FOR PRODUCING AND USING THE SAME | ORAI1, RYR2, CASR | RYR2 2/4885CDK1 585/4885MAPKAPK2 3727/4885 |
| US-20230368862-A1 | BINDING SITE IN TYPE 2 RYANODINE RECEPTOR | RYR2, RYR1, ATP2A2 | RYR2 1/4885CDK1 3991/4885MAPKAPK2 1998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.